Biomarker discovery and development in pediatric critical care medicine

被引:74
作者
Kaplan, Jennifer M.
Wong, Hector R. [1 ]
机构
[1] Univ Cincinnati, Coll Med, Div Crit Care Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA
基金
美国国家卫生研究院;
关键词
biomarker discovery and development; pediatric intensive care unit; multibiomarker-based risk model; pediatric septic shock; procalcitonin; interleukin-8; acute kidney injury; C-REACTIVE PROTEIN; GELATINASE-ASSOCIATED LIPOCALIN; ACUTE KIDNEY INJURY; CALCITONIN-I GENE; INFLAMMATORY RESPONSE; BACTERIAL-INFECTION; ILL CHILDREN; SYSTEMIC INFLAMMATION; SERUM PROCALCITONIN; SEPSIS;
D O I
10.1097/PCC.0b013e3181e28876
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: To frame the general process of biomarker discovery and development; and to describe a proposal for the development of a multibiomarker-based risk model for pediatric septic shock. Data Source: Narrative literature review and author-generated data. Data Selection: Biomarkers can be grouped into four broad classes, based on the intended function: diagnostic, monitoring, surrogate, and stratification. Data Extraction and Synthesis: Biomarker discovery and development requires a rigorous process, which is frequently not well followed in the critical care medicine literature. Very few biomarkers have successfully transitioned from the candidate stage to the true biomarker stage. There is great interest in developing diagnostic and stratification biomarkers for sepsis. Procalcitonin is currently the most promising diagnostic biomarker for sepsis. Recent evidence suggested that interleukin-8 can be used to stratify children with septic shock having a high likelihood of survival with standard care. Currently, there is a multi-institutional effort to develop a multibiomarker-based sepsis risk model intended to predict outcome and illness severity for individual children with septic shock. Conclusions: Biomarker discovery and development are an important portion of the pediatric critical care medicine translational research agenda. This effort will require collaboration across multiple institutions and investigators. Rigorous conduct of biomarker-focused research holds the promise of transforming our ability to care for individual patients and our ability to conduct clinical trials in a more effective manner. (Pediatr Crit Care Med 2011; 12:165-173)
引用
收藏
页码:165 / 173
页数:9
相关论文
共 61 条
  • [1] The human plasma proteome - History, character, and diagnostic prospects
    Anderson, NL
    Anderson, NG
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) : 845 - 867
  • [2] HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION
    ASSICOT, M
    GENDREL, D
    CARSIN, H
    RAYMOND, J
    GUILBAUD, J
    BOHUON, C
    [J]. LANCET, 1993, 341 (8844) : 515 - 518
  • [3] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    Atkinson, AJ
    Colburn, WA
    DeGruttola, VG
    DeMets, DL
    Downing, GJ
    Hoth, DF
    Oates, JA
    Peck, CC
    Schooley, RT
    Spilker, BA
    Woodcock, J
    Zeger, SL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
  • [4] Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target
    Becker, Kenneth L.
    Snider, Richard
    Nylen, Eric S.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (02) : 253 - 264
  • [5] Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
    Bouadma, Lila
    Luyt, Charles-Edouard
    Tubach, Florence
    Cracco, Christophe
    Alvarez, Antonio
    Schwebel, Carole
    Schortgen, Frederique
    Lasocki, Sigismond
    Veber, Benoit
    Dehoux, Monique
    Bernard, Maguy
    Pasquet, Blandine
    Regnier, Bernard
    Brun-Buisson, Christian
    Chastre, Jean
    Wolff, Michel
    [J]. LANCET, 2010, 375 (9713) : 463 - 474
  • [6] Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin
    Brunkhorst, FM
    Eberhard, OK
    Brunkhorst, R
    [J]. CRITICAL CARE MEDICINE, 1999, 27 (10) : 2172 - 2176
  • [7] Byvatov Evgeny, 2003, Appl Bioinformatics, V2, P67
  • [8] Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma
    Castelli, Gian Paolo
    Pognani, Claudio
    Cita, Massimo
    Paladini, Rolando
    [J]. CRITICAL CARE MEDICINE, 2009, 37 (06) : 1845 - 1849
  • [9] Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates
    Cusumano, V
    Midiri, A
    Cusumano, VV
    Bellantoni, A
    De Sossi, G
    Teti, G
    Beninati, C
    Mancuso, G
    [J]. INFECTION AND IMMUNITY, 2004, 72 (01) : 295 - 300
  • [10] PROCALCITONIN INCREASE AFTER ENDOTOXIN INJECTION IN NORMAL SUBJECTS
    DANDONA, P
    NIX, D
    WILSON, MF
    ALJADA, A
    LOVE, J
    ASSICOT, M
    BOHUON, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06) : 1605 - 1608